Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease

The non-vitamin K antagonist oral anticoagulants (NOACs) dabigatran, rivaroxaban, apixaban, and edoxaban have transformed the management of atrial fibrillation (AF), but are only approved by regulatory authorities for stroke prophylaxis in patients with so-called “non-valvular AF.” This terminology...

Descripción completa

Detalles Bibliográficos
Autores principales: Fanaroff, Alexander C, Vora, Amit N, Lopes, Renato D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Supplement Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850709/
https://www.ncbi.nlm.nih.gov/pubmed/35185406
http://dx.doi.org/10.1093/eurheartj/suab151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850709/
https://www.ncbi.nlm.nih.gov/pubmed/35185406
http://dx.doi.org/10.1093/eurheartj/suab151

Ejemplares similares